Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis: A meta-analysis and trial sequential analysis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-7)

Tables (1-3)

Sum=0

Jul 26, 2024 (publication date) through Jun 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Cases. Jul 26, 2024; 12(21): 4703-4716
Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4703

Table 2 The results of meta-analysis and trial sequential analysis for safety endpoints

Outcome	Experimental	Control	I²	RR (95%CI)	P value	TSA
Total adverse events	21/226	19/224	0	1.10 (0.61-1.97)	0.75	No
Gastrointestinal adverse events	11/168	10/166	0	1.08 (0.50-2.36)	0.84	No
Abdominal distension	3/73	3/72	0	0.99 (0.23-4.22)	0.99	No
Erythra	3/130	3/128	0	0.98 (0.27-3.57)	0.98	No
Relapse	12/116	29/115	50	0.41 (0.22-0.76)	0.005	Yes

TSA: Trial sequential analysis; RR: Risk ratio.

Citation: Yang XY, Yu YF, Tong KK, Hu G, Yu R, Su LJ. Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis: A meta-analysis and trial sequential analysis. World J Clin Cases 2024; 12(21): 4703-4716
URL: https://www.wjgnet.com/2307-8960/full/v12/i21/4703.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i21.4703